Effect of Dexmedetomidine on Posttraumatic Stress Disorder in Patients Undergoing Emergency Trauma Surgery
Importance
Posttraumatic stress disorder (PTSD) is common in people who have experienced trauma, especially those hospitalized for surgery. Dexmedetomidine may reduce or reverse the early consolidation and formation of conditioned fear memory and prevent the occurrence of postoperative PTSD.
Objective
To evaluate the effects of intraoperative and postoperative low-dose intravenous pumping dexmedetomidine on PTSD among patients with trauma undergoing emergency surgery.
Design, Setting, and Participants
This double-blind, randomized clinical trial was conducted from January 22 to October 20, 2022, with follow-up 1 month postoperatively, in patients with trauma undergoing emergency surgery at 4 hospital centers in Jiangsu Province, China. A total of 477 participants were screened. The observers were blinded to patient groupings, particularly for subjective measurements.
Interventions
Dexmedetomidine or placebo (normal saline) was administered at a maintenance dose of 0.1 μg/kg hourly from the start of anesthesia until the end of surgery and at the same rate after surgery from 9 pm to 7 am on days 1 to 3.
Main Outcomes and Measures
The primary outcome was the difference in the incidence of PTSD 1 month after surgery in the 2 groups. This outcome was assessed with the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (CAPS-5). The secondary outcomes were the pain score within 48 hours and 1 month postoperatively; incidence of postoperative delirium, nausea, and pruritus; subjective sleep quality; anxiety; and occurrence of adverse events.
Results
A total of 310 patients (154 in the normal saline group and 156 in the dexmedetomidine group) were included in the modified intention-to-treat analysis (mean [SD] age, 40.2 [10.3] years; 179 men [57.7%]). The incidence of PTSD was significantly lower in the dexmedetomidine group than in the control group 1 month postoperatively (14.1% vs 24.0%; P = .03). The participants in the dexmedetomidine group had a significantly lower CAPS-5 score than those in the control group (17.3 [5.3] vs 18.9 [6.6]; mean difference, 1.65; 95% CI, 0.31-2.99; P = .02). After adjusting for potential confounders, the patients in the dexmedetomidine group were less likely to develop PTSD than those in the control group 1 month postoperatively (adjusted odds ratio, 0.51; 95% CI, 0.27-0.94; P = .03).
Conclusions and Relevance
In this randomized clinical trial, the administration of intraoperative and postoperative dexmedetomidine reduced the incidence of PTSD among patients with trauma. The findings of this trial support the use of dexmedetomidine in emergency trauma surgery.
Trial Registration
Chinese Clinical Trial Register Identifier:
Top-30
Journals
|
1
2
|
|
|
BMJ Open
2 publications, 7.14%
|
|
|
Anesthesiology
2 publications, 7.14%
|
|
|
Clinical and Experimental Obstetrics and Gynecology
2 publications, 7.14%
|
|
|
Critical Care
1 publication, 3.57%
|
|
|
Seminars in Neurology
1 publication, 3.57%
|
|
|
Frontiers in Pharmacology
1 publication, 3.57%
|
|
|
PLoS ONE
1 publication, 3.57%
|
|
|
Journal of Biochemical and Molecular Toxicology
1 publication, 3.57%
|
|
|
International Journal of Obstetric Anesthesia
1 publication, 3.57%
|
|
|
Progress in Brain Research
1 publication, 3.57%
|
|
|
Progress in Neuro-Psychopharmacology and Biological Psychiatry
1 publication, 3.57%
|
|
|
European Archives of Psychiatry and Clinical Neuroscience
1 publication, 3.57%
|
|
|
CNS Neuroscience and Therapeutics
1 publication, 3.57%
|
|
|
Journal of Clinical Anesthesia
1 publication, 3.57%
|
|
|
Journal of Advanced Research
1 publication, 3.57%
|
|
|
Critical Care Clinics
1 publication, 3.57%
|
|
|
Anesthesia and Analgesia
1 publication, 3.57%
|
|
|
Scientific Reports
1 publication, 3.57%
|
|
|
Inflammopharmacology
1 publication, 3.57%
|
|
|
Drug Design, Development and Therapy
1 publication, 3.57%
|
|
|
Frontiers in Medicine
1 publication, 3.57%
|
|
|
Translational Pediatrics
1 publication, 3.57%
|
|
|
International Journal of Clinical Practice
1 publication, 3.57%
|
|
|
Journal of Molecular Neuroscience
1 publication, 3.57%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
6
|
|
|
Elsevier
6 publications, 21.43%
|
|
|
Springer Nature
5 publications, 17.86%
|
|
|
Wiley
3 publications, 10.71%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
3 publications, 10.71%
|
|
|
Frontiers Media S.A.
2 publications, 7.14%
|
|
|
BMJ
2 publications, 7.14%
|
|
|
IMR Press
2 publications, 7.14%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 3.57%
|
|
|
Georg Thieme Verlag KG
1 publication, 3.57%
|
|
|
Public Library of Science (PLoS)
1 publication, 3.57%
|
|
|
Taylor & Francis
1 publication, 3.57%
|
|
|
AME Publishing Company
1 publication, 3.57%
|
|
|
1
2
3
4
5
6
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.